MARKET

OCUL

OCUL

Ocular Therapeut
NASDAQ
9.65
-0.11
-1.13%
Opening 14:52 06/26 EDT
OPEN
9.78
PREV CLOSE
9.76
HIGH
10.09
LOW
9.63
VOLUME
1.28M
TURNOVER
--
52 WEEK HIGH
16.44
52 WEEK LOW
6.23
MARKET CAP
2.11B
P/E (TTM)
-6.6287
1D
5D
1M
3M
1Y
5Y
1D
Ocular Therapeutix Is Maintained at Buy by Chardan Capital
Dow Jones · 1d ago
Ocular Therapeutix Price Target Raised to $23.00/Share From $21.00 by Chardan Capital
Dow Jones · 1d ago
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23
Benzinga · 1d ago
Analysts Conflicted on These Healthcare Names: Repligen (RGEN), Exelixis (EXEL) and Ocular Therapeutix (OCUL)
TipRanks · 1d ago
Ocular Therapeutix grants new SVP inducement awards of 85,000 stock options, 28,000 RSUs
PUBT · 3d ago
OCULAR THERAPEUTIX™ REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 3d ago
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Ocular Therapeutix (OCUL)
TipRanks · 4d ago
Analysts Are Bullish on These Healthcare Stocks: NovoCure (NVCR), Ocular Therapeutix (OCUL)
TipRanks · 4d ago
More
About OCUL
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.

Webull offers Ocular Therapeutix Inc stock information, including NASDAQ: OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.